The World Health Organization (WHO) has requested that Chinese vaccine producer Sinovac Biotech (Nasdaq: SVA) share more data as they seek to assess whether to authorize a second Chinese SARS-CoV-2 vaccine for use around the world. Called CoronaVac, WHO specifically needs more information about safety and more granular details about the manufacturing processes employed by the company. WHO’s question: does Sinovac’s quality processes match those required by WHO for authorization? This is no trivial matter, as a great vaccine imbalance exists between rich and poor countries and another emergency authorized vaccine could make a material difference in closing that gap.
The Wall Street Journal reported on the requests recently. Last month, WHO gave the greenlight for the first time to a Chinese vaccine maker known as Sinopharm Group. While one insider at WHO suggests a CoronaVac decision may not occur until June, the urgency of the pandemic most certainly merits expedited review. Just a few weeks ago, the European Medicines Agency (EMA) initiated a rolling review of the Sinovac vaccine.
The CoronaVac is used by select countries in Asia, as well as South America, Mexico, and Europ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).